The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,362,065 in first-year total cost, median $1,181,033.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-A (11)]1
- Special Emphasis Panel[ZRG1 ETTN-C (10)]1
Most frequent institutions
- MYOLEX, INC.1
- REVERAGEN BIOPHARMA, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Pivotal trial of vamorolone in Duchenne muscular dystrophy2R44NS095423-03 | CLEMENS, PAULA RHOFFMAN, ERIC P. | REVERAGEN BIOPHARMA, INC., MD | $1,500,000 | ZRG1 |
| 2018 | Electrical impedance myography technology for quantitative, at-home muscle assessment in amyotrophic lateral sclerosis and other neuromuscular disorders.2R44NS070385-05 | LUPTON, ELMER CRUTKOVE, SEWARD B. | MYOLEX, INC., MA | $862,065 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.